Concepedia

Aiman Shalabi

AS

Statistics

Publications

7

Citations

517

H-Index

7

Active since

2002

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Harvard University

National Cancer Institute

Aiman Shalabi is an author at Memorial Sloan Kettering Cancer Center specializing in pharmacology, pharmacy, and cancer immunotherapy.

Publications per year

2002–2021

7

Publications

7

Glucarpidase, Leucovorin, and Thymidine for High-Dose Methotrexate-Induced Renal Dysfunction: Clinical and Pharmacologic Factors Affecting Outcome

Brigitte C. Widemann, Frank M. Balis, AeRang Kim et al. · Journal of Clinical Oncology · 2010 · 173 citations · Full text

, , +17

ASHP Guidelines on Preventing Medication Errors with Antineoplastic Agents

David Köhler, Michael Montello, Barry R. Goldspiel et al. · American Journal of Health-System Pharmacy · 2002 · 122 citations · Full text

, , +16

A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors.

Jose Lutzky, Scott Antonia, Andy Blake-Haskins et al. · Journal of Clinical Oncology · 2014 · 104 citations

, , +17

Treatment of Accidental Intrathecal Methotrexate Overdose With Intrathecal Carboxypeptidase G2

Brigitte C. Widemann, Frank M. Balis, Aiman Shalabi et al. · JNCI Journal of the National Cancer Institute · 2004 · 71 citations · Full text

, , +13

Pharmacokinetics of MEDI4736, a fully human anti-PDL1 monoclonal antibody, in patients with advanced solid tumors.

David Fairman, Rajesh Narwal, Meina Liang et al. · Journal of Clinical Oncology · 2014 · 26 citations

, , +17

1–5 of 7